Sistema de Información Esencial en Terapéutica y Salud

@SIETES7

Última actualización: 9/11/2018
SIETES contiene 92577 citas

 
 
 1 a 19 de 19 
Presentar resultados
Seleccionar todas
1. Cita con resumen
Sheppard JP, Stevens S, Stevens R, Martin U, Mant J, Richard Hobbs FD, McManus RJ. Benefits and harms of antihypertensive treatment in low-risk patients with mild hypertension. JAMA Intern Med 2018:29 de octubre. [Ref.ID 102837]
2. Cita con resumen
Xie X, Atkins E, Lv J, Bennett A, Neal B, Ninomiya T, Woodward M, McMahon S, Turnbull F, Hillis GS, Chalmers J, Mant J, Salam A, Rahími K, Perkovic V, Rodgers A. Effect of intensive blood pressure lowering on cardiovascular and renal outcomes: updated systematic review and meta-analysis. Lancet 2016;387:435-43. [Ref.ID 100094]
3.Tiene citas relacionadas
Lasserson D, Mant J. The role of dipeptidyl peptidase-4 inhibitors. BMJ 2012;344:7. [Ref.ID 92655]
4.Enlace a cita originalTiene citas relacionadas
Al-Mohammad A, Mant J, Laramee P, Swain S, on behalf of the Chronic Heart Failure Guideline Development Group. Diagnosis and management of adults with chronic heart failure: summary of updated NICE guidance. BMJ 2010;341:450-2. [Ref.ID 89262]
5.Tiene citas relacionadas
McManus RJ, Mant J. Management of blood pressure in primary care. BMJ 2009;338:1219-20. [Ref.ID 85955]
6. Cita con resumen
Home P, Mant J, Díaz J, Turner C, on behalf of the Guideline Development Group. Management of type 2 diabetes: updated NICE guidance. BMJ 2008;336:1306-8. [Ref.ID 83216]
7.Tiene citas relacionadas
Mant J, Hobbs FD, Fletcher K, Roalfe A, Fitzmaurice D, on behalf of the BAFTA investigators and the Midland Research Practices Network (MidReC). Warfarin versus aspirin for stroke prevention (BAFTA). Authors' reply. Lancet 2007;370:1606-7. [Ref.ID 81478]
8.Tiene citas relacionadas Cita con resumen
Mant J, Hobbs FDR, Fletcher K, Roalfe A, Fitzmaurice D, Lip GYH, Murray E, on behalf of the BAFTA investigators and the Midland Research Practices Network (MidReC). Warfarin versus aspirin for stroke prevention in an elderly community population with atrial fibrillation (the Birmingham Atrial Fibrillation Treatment of the Aged Study, BAFTA): a randomised controlled trial. Lancet 2007;370:493-503. [Ref.ID 80885]
10.
McManus RJ, Mant J, Roalfe A, Oakes RA, Bryan S, Pattison HM, Hobbs FDR. Targets and self monitoring in hypertension: randomised controlled trial and cost effectiveness analysis. BMJ 2005;331:493-6. [Ref.ID 74732]
11. Cita con resumen
McManus RJ, Mant J, Meulendijks CFM, Salter RA, Pattison H M, Roalfe A K, Hobbs FDR, on behalf of the Midlands Research Practice Consortium. Comparison of estimates and calculations of risk of coronary heart disease by doctors and nurses using different calculation tools in general practice: cross sectional study. BMJ 2002;324:459-64. [Ref.ID 60586]
12.Tiene citas relacionadas
Mant J, Fitzmaurice D, Murray E, Lip GYH, Hobbs FDR. Long term anticoagulation or antiplatelet treatment. Inclusion criteria determine results of review. BMJ 2001;323:233-4. [Ref.ID 57644]
15.Tiene citas relacionadas
16.
Mant J, Winner S, Carter J, Wade DT. Informed consent. Patients' knowledge that they are participating in trial may not bias results. BMJ 1997;315:252-3. [Ref.ID 33695]
17.
Lancaster T, Mant J, Singer DE. Stroke prevention in atrial fibrillation. BMJ 1997;314:1563-4. [Ref.ID 32544]
19.
Mant J, Gatherer A. Managing clinical risk. BMJ 1994;308:1522-3. [Ref.ID 21961]
Seleccionar todas
 
 1 a 19 de 19